The major objective of this course is to provide a detailed insight into the practical aspects and approaches of process scale-up for different unit operations and technologies.
Interview with Lenka Francišković
Read the interview with Lenka Francišković, Quality Management, Head of Processes and Products Quality, Belupo
- Which Cost of Quality-related approaches and methodologies do you consider to be the best?
Cost of quality can be divided into the cost of good quality and the cost of poor quality. As it is too much of an effort to be able to calculate both costs, it is beneficial to calculate the cost of poor quality. By looking into the cost of poor quality, one is able to see where improvements are possible.
- From your experience, what can the impact of the cost of poor quality be?
It is very difficult to assume the impact of the cost of poor quality if you do not start collecting information on the cost of poor quality. It is only when the company decides to collect information on poor quality that many hidden situations are revealed and the actual cost and impact of poor quality is highlighted. There are still costs that are not accounted for such as the cost of market loss as a result of bad quality, the cost of reputation as a company and so on.
- How long have you applied the Cost of Quality methodology in Belupo? What are the main improvements you've achieved so far?
For several years, we have been looking into the cost of poor quality. The main achievement reached by this exercise is that the culture of doing something right the first time is understood by personnel. This changed the company’s culture of redoing a process because an actual cost can be calculated and the losses are known; therefore, the avoidance of such an event is built into the culture more and more with time.
- What is your biggest expectation for the upcoming conference?
I am curious to hear if any of the present companies are calculating the cost of poor quality and what their experiences are. And generally speaking, I am curious to touch upon several quality management topics with professionals from Russian and EU companies such as change control implementation and the filing of variations to Russian agencies. Besides, I learned the Russian language throughout my schooling and I would like to implement it in a real environment.
Interested in this topic?
Targeted Drug Delivery
Gain detailed overview of the newest strategies in drug delivery and targeting.
Next Generation Antibody Therapeutics
This focused 2-day training will cover the discovery, engineering and production of next-generation antibodies, antibody fragments, bispecific Abs, innovative ADCs and more. Follow the path from their discovery and selection through engineering and expression to production and regulatory issues.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?